Occam Places Jeb Ledell as COO at Aveo Oncology
AVEO Oncology (Nasdaq: AVEO) is a commercial stage, oncology-focused biopharmaceutical company. Aveo was acquired by LG Chem for $600M in October of 2022.
In late 2021, Occam placed Jeb Ledell as COO of AVEO. Jeb joined AVEO from Enzyvant Therapeutics, a biotech company dedicated to developing novel, transformative regenerative therapies with rare diseases, where he served as COO. Prior to Enzyvant, Jeb served as COO at Compass Therapeutics and Horizon Discovery Group.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.